Molecular Therapeutics

Type: Company

Name: Molecular Therapeutics

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Sangamo Biosciences Inc Announces New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics For Monogenic Diseases

Sangamo Biosciences Inc announced the presentation of new data demonstrating the successful application of Sangamo's In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered ... [Published Reuters - May 20 2013]

Entities: Sangamo BioSciences Inc, In Vivo, Protein, Therapeutics

First reported Mar 11 2013 - Updated Mar 11 2013 - 1 reports

European Commission

Orphan designation: Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene, for the: Treatment of primary hyperoxaluria type 1

On 21 March 2012, orphan designation (EU/3/12/974) was granted by the European Commission to Amsterdam Molecular Therapeutics BV, the Netherlands, for adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase ... [Published Orphan designations - Mar 11 2013]

Entities: viral vector, Molecular Therapeutics, Amsterdam, European Commission

First reported Feb 25 2013 - Updated Feb 25 2013 - 1 reports

Scripps Research Institute

What Overeating Does To Your Body

Wall Street is an easy place to pick up the habit of overeating. Think about it: It's a place that embraces taking clients out to lavish dinners, working long days and sometimes splurging on meals to make up for those miserable hours. And then there's ... [Published Clusterstock - Feb 25 2013]

Entities: Molecular Therapeutics, Paul Kenny, Scripps Research Institute, University of Montreal

Quotes

...Vivus Board has proven to be poor stewards of shareholder capital," commented Sam Colin, M D , Senior Managing Director at FMC and a Board nominee. "Qsymia's potential is substantial. However, Vivus has badly mismanaged the Qsymia launch, and neither the recent REMS modification nor the addition of a new director will cure the root cause of the failure. Vivus and its shareholders deserve a Board worthy of Qsymia. Our slate of six highly qualified nominees has the independence, the experience, and the plan to fix the Company before time runs out."

First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivu [Published Daily Finance - May 01 2013]

"We are pleased that Vivus has chosen to add a new director with large pharma experience and one who has been associated with a long-standing shareholder. It is a sad statement that multiple failed attempts to launch Qsymia, an obesity drug with blockbuster potential, were clearly not enough to prod this Board into action. It was only in response to FMC's campaign to elect our six highly qualified nominees that the current Board has chosen to act."

First Manhattan Comments on Addition to Vivus' Board of Directors [Published Zecco - May 01 2013]

...to expand our scientific and medical teams essential for transition to a clinical stage company," stated Thomas W Gardner, CEO of AtheroNova. "Dr. Kastelein's leadership in the area of lipidology and his Lipid Research Clinic in Amsterdam has been an integral part of many atherogenesis studies including IDEAL, TNT, CAPTIVATE, ENHANCE, ILLUMINATE, JUPITER and RADIANCE. We feel that adding Dr. Kastelein to the AtheroNova team is significant in its impact on the knowledge he will contribute to our clinical efforts."

Noted Atherosclerosis Researcher Joins AtheroNova Team [Published BioMedReports - Apr 15 2013]

...Joe Bass, a Northwestern University endocrinologist and molecular biologist who has published numerous studies about the body clock and mice. "It would be as if you were waking up every night during holiday season and eating all the sweets in your refrigerator."

What Overeating Does To Your Body [Published Clusterstock - Feb 25 2013]

More Content

sort by: Date \| Relevance
Sangamo Biosciences Inc Announces New Data From... [Published Reuters - May 20 2013]
Sangamo BioSciences Presents New Data From In V... [Published TickerTech.com - May 20 2013]
First Manhattan Files Preliminary Proxy Materia... [Published Daily Finance - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Equities.com - May 01 2013]
First Manhattan Responds to VIVUS Board Additio... [Published Benzinga.com - May 01 2013]
VIVUS, INC.: First Manhattan Comments on Additi... [Published 4 Traders - May 01 2013]
First Manhattan Comments on Addition to Vivus' ... [Published Zecco - May 01 2013]
Noted Atherosclerosis Researcher Joins AtheroNo... [Published Digital Journal - Apr 17 2013]
Noted Atherosclerosis Researcher Joins AtheroNo... [Published TickerTech.com - Apr 17 2013]
Noted Atherosclerosis Researcher Joins AtheroNo... [Published BioMedReports - Apr 15 2013]
/C O R R E C T I O N -- AtheroNova Inc./ [Published TickerTech.com - Apr 15 2013]
AtheroNova Adds New Medical Advisor [Published Sys-Con Australia - Apr 15 2013]
Aprea to present at the American Association fo... [Published CisionWire - English - Apr 03 2013]
Jasco Pharmaceuticals to Present its Preclinica... [Published Yahoo! Finance - Apr 01 2013]
Orphan designation: Adeno-associated viral vect... [Published Orphan designations - Mar 11 2013]
What Overeating Does To Your Body [Published Clusterstock - Feb 25 2013]
Naurex Raises $38M [Published PE Hub News - Dec 17 2012]